摘要
目的 观察阿伦膦酸钠对妇女原发性骨质疏松症的有效性和安全性。方法 2 5例原发性骨质疏松症妇女每日口服阿伦膦酸钠 10mg和元素钙 5 0 0mg(碳酸钙 )疗程 12月。通过双能X线吸收仪 (DEXA)、定量CT(QCT)、胫骨超声速率 (SOS)及生化指标观察治疗中及治疗后的骨量及骨转换的变化。结果 DEXA骨密度L2～ 4于治疗 3个月、6个月和 12个月时均较治疗前有显著升高 (P <0 0 1) ,升高率分别为 3 3 %、4 4%和 7 2 %。股骨近端骨密度也有升高 ;经QCT检查的腰椎 (L1～ 4 )骨密度于治疗 12个月时显著增加 (8 1% ,P <0 0 1) ;胫骨超声速率于治疗的 6个月、9个月和 12个月时较治疗前分别增加 1 4% (P <0 0 5 )、1 8% (P <0 0 1)和 1 4% (P <0 0 5 )。同时治疗中伴有骨转换指标的降低。未发现与药物有关的不良反应。结论 阿伦膦酸钠
Objective\ To determine the efficiency and safety of alendronate on primary osteoporosis in women.Methods\ 25 Chinese women aged(66 8±6 4)yrs with primary osteoporosis were enrolled.All subjects received alendronate 10mg and calcium 500mg daily for 12 months.Results\ Follow-up dual energy X-ray absorptiometry showed that bone mineral density increased progressively in a significant way in lumbar spine(L 2～4 by 3 3%,4 4% and 7 2%in 3,6 and 12 months respectively)and proximal femur.BMD of L 1～4 determined by quantitative computerized tomography also increased significantly in 12 months after treatment(8 1%,P<0 001).The speed of sound on tibia rose by 1 4%(P<0 05),1 8%(P<0 01)and 1 4%(P<0 05)in 6,9 and 12 months respectively after treatment.The marker of bone turnover significantly declined after treatment.There was no adverse experience associated with alendronate during the whole study.Conclusion\ Alendronate significantly increases BMD and is well tolerated at doses of 10 mg daily in the treatment of primary osteoporosis in women.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2000年第4期214-216,共3页
Chinese Journal of Practical Internal Medicine
